Investors

Investors

American Society of Clinical Oncology (ASCO) Annual Meeting

1 June 2015

AstraZeneca will be hosting a briefing for analysts and investors during the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago on Monday 1 June 2015, from 8:30pm –10:00pm CDT (2 June 2:30am - 4:00am BST – UK). The aim of this event is to update on progress with AstraZeneca’s immuno-oncology pipeline and combination treatments.

You will be able to listen to the event using the following dial in details:

UK freephone: 0800 694 0257
US freephone: 866 966 9439
Sweden freephone: 0200 890171
International: +44 (0) 1452 555566

Conference code: 42762226

Listen to webcast


Latest downloads

ASCO 2015 Investor science event

1 June 2015

ASCO 2015 Investor science event biographies

1 June 2015

AstraZeneca Mölndal

22 May 2015

First quarter results 2015

24 April 2015

Investor science conference call ACC 2015

16 March 2015

AstraZeneca refines its financial reporting in line with evolving business model

6 March 2015

Investor Relations presentation - March 2015

5 March 2015

Fourth quarter and full year results 2014

5 February 2015

Latest press releases

AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT
16 June 2015
AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge Biomedical Campus
11 June 2015
New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin
8 June 2015
AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for the treatment of type 2 diabetes
6 June 2015
AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the American Diabetes Association 75th Scientific Sessions
3 June 2015
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
2 June 2015
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015
30 May 2015
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
29 May 2015
AstraZeneca provides update on brodalumab development programme
22 May 2015
AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio
18 May 2015
AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO 2015
13 May 2015
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
13 May 2015

Share price

London
41.67 GBP
New York
65.41 USD
Stockholm
548.50 SEK

At 4-7-2015 16:15 GMT

Detailed share price


Stock symbol - AZN

On LSE, NYE and OMX